Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 16:4:100072.
doi: 10.1016/j.eurox.2019.100072. eCollection 2019 Oct.

Use of antenatal fluorinated corticosteroids in management of congenital heart block: Systematic review and meta-analysis

Armia Michael  1 , Ahmad A Radwan  1 , Ahmed Kamel Ali  1 , Ahmed Yassien Abd-Elkariem  1 , Sherif A Shazly  2 ; Middle-East Obstetrics and Gynecology Graduate Education (MOGGE) Foundation Research Group
Affiliations
Review

Use of antenatal fluorinated corticosteroids in management of congenital heart block: Systematic review and meta-analysis

Armia Michael et al. Eur J Obstet Gynecol Reprod Biol X. .

Abstract

Objective: To evaluate outcomes of fluorinated corticosteroids, with or without other medications, for treatment of congenital heart block in-utero.

Study design: A search was conducted through MEDLINE, EMBASE, WEB OF SCIENCE and SCOPUS from inception to October 2017. Only comparative studies are considered eligible. Outcomes include fetal death, downgrade of heart block, neonatal death, need for neonatal pacing, fetal and maternal complications. Random effects model was used.

Results: Out of 923 articles, 12 studies were eligible. Compared to no treatment, there was no significant difference in incidence of fetal death (OR 1.10, 95%CI 0.65-1.84), neonatal death (OR 0.98, 95%CI 0.41-2.33), or need for pacing (OR 1.46, 95%CI 0.78-2.74). Heart block downgrade was significantly higher in treatment group (9.48%vs.1.76%, OR 3.27, 95%CI 1.23-8.71).

Conclusion: antenatal fluorinated corticosteroids do not improve fetal/neonatal morbidity or mortality of congenital heart block and are associated with higher incidence of fetal and maternal complications.

Keywords: Congenital heart disease; Fetal diagnosis; Fetal therapy; Prenatal treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study selection flow chart.
Fig. 2
Fig. 2
Fetal and neonatal outcomes of treatment versus no-treatment among fetuses with congenital heart block.
Fig. 3
Fig. 3
Fetal and neonatal outcomes of fluorinated steroids only versus no-treatment among fetuses with congenital heart block.
Fig. 4
Fig. 4
Complications of treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yan J., Varma S.K., Malhotra A., Menahem S. Congenital complete heart block: single tertiary centre experience. Heart Lung Circ. 2012;21(11):666–670. - PubMed
    1. Brito-Zerón P., Izmirly P.M., Ramos-Casals M., Buyon J.P., Khamashta M.A. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301. - PMC - PubMed
    1. Puri S., Pooni P., Mohan B., Bindal V., Verma S., Verma S., Gupta R.K. Pregnancy with SLE and fetal congenital heart block: a case report. Cardiol Res. 2013;4(3):126. - PMC - PubMed
    1. Brucato A., Frassi M., Franceschini F., Cimaz R., Faden D., Pisoni M.P., Muscarà M., Vignati G., Stramba‐Badiale M., Catelli L. Risk of congenital complete heart block in newborns of mothers with anti‐Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheumatol. 2001;44(8):1832–1835. - PubMed
    1. Grava C., Ruffatti A., Milanesi O., Favaro M., Tonello M., Calligaro A., Del Ross T., Todesco S. Isolated congenital heart block in undifferentiated connective tissue disease and in primary Sjögren’s syndrome: a clinical study of 81 pregnancies in 41 patients. Reumatismo. 2005;57(3):180–186. - PubMed